MedPath

Summit Therapeutics

🇬🇧United Kingdom
Ownership
-
Employees
105
Market Cap
$9.7B
Website
Introduction

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Clinical Trials

11

Active:2
Completed:5

Trial Phases

3 Phases

Phase 1:3
Phase 2:3
Phase 3:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 3
5 (45.5%)
Phase 1
3 (27.3%)
Phase 2
3 (27.3%)

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Phase 3
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2025-01-10
Last Posted Date
2025-04-29
Lead Sponsor
Summit Therapeutics
Target Recruit Count
780
Registration Number
NCT06767514
Locations
🇺🇸

Clinical Study Site, Webster, Texas, United States

Phase III Study of AK112 for NSCLC Patients

Phase 3
Active, not recruiting
Conditions
Non-Squamous Non-small Cell Lung Cancer
Interventions
Drug: AK112 Injection
Drug: Placebo Injection
First Posted Date
2024-05-02
Last Posted Date
2024-10-08
Lead Sponsor
Summit Therapeutics
Target Recruit Count
420
Registration Number
NCT06396065
Locations
🇺🇸

CBCC Global Research, Bakersfield, California, United States

🇺🇸

UC San Diego, La Jolla, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 70 locations

HARMONi-3

Phase 3
Recruiting
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-08-16
Last Posted Date
2025-05-30
Lead Sponsor
Summit Therapeutics Inc.
Target Recruit Count
389
Registration Number
2024-513087-26-00
Locations
🇧🇪

Werken Glorieux, Ronse, Belgium

🇧🇪

Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir, Belgium

🇸🇪

Uppsala University Hospital, Uppsala, Sweden

and more 80 locations

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Phase 3
Terminated
Conditions
Clostridioides Difficile Infection
Interventions
First Posted Date
2021-03-17
Last Posted Date
2023-08-21
Lead Sponsor
Summit Therapeutics
Target Recruit Count
2
Registration Number
NCT04802837
Locations
🇺🇸

University of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, United States

🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

Continental Clinical Research, Miami, Florida, United States

and more 15 locations

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Phase 3
Completed
Conditions
Clostridioides Difficile Infection
Interventions
First Posted Date
2018-07-23
Last Posted Date
2023-03-03
Lead Sponsor
Summit Therapeutics
Target Recruit Count
759
Registration Number
NCT03595553
Locations
🇺🇸

University of Alabama - Birmingham, Birmingham, Alabama, United States

🇺🇸

GI Alliance - Arizona Digestive Health - Sun City, Sun City, Arizona, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 146 locations
  • Prev
  • 1
  • 2
  • Next

News

AstraZeneca and Summit Therapeutics in Advanced Talks for $15 Billion Ivonescimab Licensing Deal

AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.

Revolution Medicines and Summit Therapeutics Launch Clinical Collaboration to Test RAS Inhibitor Combinations with Bispecific Antibody

Revolution Medicines and Summit Therapeutics announced a clinical collaboration to evaluate three RAS(ON) inhibitors in combination with ivonescimab, a PD-1/VEGF bispecific antibody, across multiple solid tumor types.

TOLREMO Therapeutics Strengthens Leadership with Key Appointments as TT125-802 Shows Clinical Promise

TOLREMO therapeutics has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer to strengthen leadership capabilities.

Bristol Myers Squibb Partners with BioNTech in $11.1 Billion Deal for Dual-Target Cancer Immunotherapy

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.

Summit Therapeutics' Ivonescimab Shows Promising Results in Phase 3 NSCLC Trial

Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.

Akeso Secures FDA Approval for Novel Cancer Drug While Partner Summit Therapeutics Faces Sharp Stock Decline

Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.

Summit's Ivonescimab Shows Promise in Phase III Trial Against Established Lung Cancer Therapies

Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.

Akeso Reports Positive Phase 3 Results for Ivonescimab in Lung Cancer, Building on Recent FDA Approval Success

Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.

BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC

BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.

Summit Therapeutics Partners with Pfizer to Evaluate Novel Cancer Drug Combination Amid Financial Losses

Summit Therapeutics announces strategic collaboration with Pfizer to evaluate their cancer drug ivonescimab in combination with Pfizer's antibody drug conjugates for solid tumor treatment.

© Copyright 2025. All Rights Reserved by MedPath